(Q35842500)

10 August 2017

1 reference

title

Recent developments in target identification against hepatitis C virus (English)

1 reference

10 August 2017

1 reference

Darius Moradpour

3

0 references

author name string

Volker Brass

series ordinal

1

1 reference

10 August 2017

Hubert E Blum

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Expert Opinion on Therapeutic Targets

10 August 2017

published in

1 reference

10 August 2017

volume

8

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

295-307

1 reference

Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Is severe liver disease a common outcome for people with chronic hepatitis C?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Projecting future complications of chronic hepatitis C in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Hepatitis C: molecular virology and antiviral targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Efficient initiation of HCV RNA replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Hepatitis C virus replicons: potential role for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Binding of hepatitis C virus to CD81

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Peptide-based inhibitors of the hepatitis C virus serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Product inhibition of the hepatitis C virus NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Inhibition of HCV NS3 protease by RNA aptamers in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Hepatitis C virus replication in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Biological evaluation of hepatitis C virus helicase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Nucleic-acid therapeutics: basic principles and recent applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Role for a bidentate ribonuclease in the initiation step of RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Interference of hepatitis C virus RNA replication by short interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Inhibition of hepatitis B virus in mice by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Short interfering RNA confers intracellular antiviral immunity in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

The challenge of developing a vaccine against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Vaccination of chimpanzees against infection by the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

DNA vaccines for hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Perspectives: towards a peptide-based vaccine against hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Protection against persistence of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

Structural biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

A proposed system for the nomenclature of hepatitis C viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.4.295

21 January 2018

Identifiers

DOI

10.1517/14728222.8.4.295

1 reference

10 August 2017

1 reference